Altum Pharmaceuticals
  • About
    • History
    • Board of Directors
    • Management
    • Advisors
  • Disease Areas & Unmet Need
    • COVID-19
    • Cervical Dysplasia/Cancer and Human Papilloma Virus (HPV)
    • Cancer Bone Metastases & Skeletal Related Events
  • Pipeline
    • Pipeline Overview
    • AP-001
    • AP-002
    • AP-003
    • BiPhasix™ Platform
  • News & Events
  • Contact
Select Page

Altum Pharmaceuticals Enters into Agreement with Ortac Capital & Ortac AG

by MTECH Support | Jun 20, 2016 | Altum Pharmaceuticals, Business, Ortac

Vancouver, British Columbia, June 20, 2016 – Altum Pharmaceuticals Inc. (“Altum” or the “Company”), is pleased to announce that it has entered into an agreement with Ortac Capital & Ortac AG (“Ortac), a Zurich based investment intermediates firm, to raise...

Recent Posts

  • Altum Pharma Appoints New Executive Chair of the Board of Directors
  • Altum Pharmaceuticals, Inc. completes acquisition of Lexi Pharma Inc, and its pipeline of novel therapies for bone disease and oncology
  • Altum Signs Exclusive Worldwide License Agreement
  • Altum Pharmaceuticals Enters into Agreement with Ortac Capital & Ortac AG

Archives

  • October 2018
  • April 2018
  • March 2017
  • June 2016
  • Privacy
  • Terms of Use
  • Cookie Policy
  • English
  • German
© 2020 Altum Pharmaceuticals Inc. All rights reserved.
We use cookies, including 3rd party cookies (e.g. Google, LinkedIn) to improve your experience on our website, analyse our traffic. By continuing to use this website, you accept our cookie policy.AcceptCookie policy